North America Thalassemia Market Size & Outlook, 2030

Revenue, 2023 (US$M)

$363.4

Forecast, 2030 (US$M)

$596.4

CAGR, 2024 - 2030

7.3%

Report Coverage

North America

North America thalassemia market, 2018-2030 (US$M)

Related Markets

Global Thalassemia Industry Outlook

Europe Thalassemia Market Outlook

Asia Pacific Thalassemia Market Outlook

Latin America Thalassemia Market Outlook

MEA Thalassemia Market Outlook

North America thalassemia market highlights

An overview of the North America thalassemia market trends heading towards 2030. The North America market generated a revenue of USD 363.4 million in 2023.
The overall growth of the North America market from 2023 to 2030. The market is expected to grow at a CAGR of 7.3% from 2024 to 2030.
A look at the North America market revenues per segment in 2023. In terms of segment, iron chelating drugs was the largest revenue generating treatment in 2023.
The segment witnessing the fastest revenue growth within the market. Iron Chelating Drugs is the most lucrative treatment segment registering the fastest growth during the forecast period.

North America data book summary

Market revenue in 2023	USD 363.4 million
Market revenue in 2030	USD 596.4 million
Growth rate	7.3% (CAGR from 2023 to 2030)
Largest segment	Iron chelating drugs
Fastest growing segment	Iron Chelating Drugs
Historical data covered	2018 - 2022
Base year for estimation	2023
Forecast period covered	2024 - 2030
Quantitative units	Revenue in USD million
Market segmentation	Iron Chelating Drugs

Other key industry trends

In terms of revenue, North America region accounted for 42.8% of the global thalassemia market in 2023.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
Asia Pacific is the fastest growing regional market and is projected to reach USD 326.4 million by 2030.

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Thalassemia Market Scope

Thalassemia market segmentation & scope

Treatment

Iron Chelating Drugs

Erythyroid maturation agents

Stem Cell therapy

Others

Indication

Alpha Thalassemia

Beta Thalassemia

Regions

Latin America

Europe

North America

Middle East & Africa

Asia Pacific

Countries

U.S.

Canada

Mexico

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Japan

China

India

Australia

South Korea

Thailand

Brazil

Argentina

South Africa

Saudi Arabia

UAE

Kuwait

Thalassemia Market Companies

Name	Profile	# Employees	HQ	Website

North America thalassemia market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to thalassemia market will help companies and investors design strategic landscapes.

Iron chelating drugs was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the North America thalassemia market based on iron chelating drugs covering the revenue growth of each sub-segment from 2018 to 2030.

Reasons to subscribe to North America thalassemia market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of North America thalassemia market databook

Our clientele includes a mix of thalassemia market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the North America thalassemia market , including forecasts for subscribers. This continent databook contains high-level insights into North America thalassemia market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list